We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Ground-Breaking Phage-Based Diagnostic Kit for Laboratory Tuberculosis Testing Presented at AACC 2023

By LabMedica International staff writers
Posted on 27 Jul 2023

Improved diagnostic tests for latent tuberculosis infection are crucial to better identify individuals at the highest risk of progressing to active tuberculosis. More...

Diagnostic laboratories play a key role in combating TB and require innovative techniques to identify and isolate Mycobacterium tuberculosis (Mtb), the causative agent of the disease. At the AACC Clinical Lab Expo, PBD Biotech (Birmingham, UK) is showcasing Actiphage, a phage-based test that detects Mtb in the blood – which is considered an early indicator of ‘active’ TB disease. The test shows potential for screening latent TB and drug management. Actiphage combines phage-based DNA extraction with polymerase chain reaction to identify low levels of viable Mtb in blood.

Actiphage was also highlighted in the AACC webinar titled "Phage-Based Laboratory Diagnostics Role in the Detection of Tuberculosis," sponsored by PBD Biotech. At the webinar, experts discussed the epidemiology of tuberculosis and the limitations of current tests that assess host response. Attendees gained insights into how phage-based diagnostic technology can be employed to detect incipient and active TB. PBD Biotech recently launched one of the largest clinical trials to date for Actiphage TB, which builds upon a previous study that demonstrated the detection of Mtb in the blood of naive pulmonary TB patients. Furthermore, PBD Biotech has successfully secured a US patent for its diagnostic kit associated with Mycobacteria detection using bacteriophages, specifically relating to the diagnostic kit. This further strengthens the protection for the Actiphage technology.

“We already have a granted US Patent for the specific method steps, but this new allowance relates to the specific components that make up the Actiphage TB diagnostic kit, strengthening our rights,” said Jane Theaker CEO of PBD Biotech. “We are particularly pleased with this result, claims covering diagnostic kits are notoriously difficult to obtain before the USPTO as the components of the kit are generally considered individually and not in relation to how the kit is to be used.”

Related Links:
PBD Biotech 


Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LiDia-SEQ aims to deliver near-patient NGS testing capabilities to hospitals, labs and clinics (Photo courtesy of DNAe)

World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device

Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.